Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.
about
Receptor heteromerization and drug discovery.Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonismDifferential regulation of morphine antinociceptive effects by endogenous enkephalinergic system in the forebrain of mice.Role of antibodies in developing drugs that target G-protein-coupled receptor dimers.How to design an opioid drug that causes reduced tolerance and dependence.Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity.Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain.Exploring a role for heteromerization in GPCR signalling specificity.Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.Prolonged morphine treatment alters δ opioid receptor post-internalization traffickingLigand requirements for involvement of PKCε in synergistic analgesic interactions between spinal μ and δ opioid receptors.G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding.Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain.Effects of combined opioids on pain and mood in mammals.Behavioral consequences of delta-opioid receptor activation in the periaqueductal gray of morphine tolerant ratsDisease-specific heteromerization of G-protein-coupled receptors that target drugs of abuseFunctional relevance of μ-δ opioid receptor heteromerization: a role in novel signaling and implications for the treatment of addiction disorders: from a symposium on new concepts in mu-opioid pharmacology.Evidence from basic research for opioid combinations.An integrated quantitative proteomics and systems biology approach to explore synaptic protein profile changes during morphine exposure.Combined administration of oxycodone/naloxone in chronic osteo-articular diseases pain therapy.G-protein-coupled receptor type A heteromers as an emerging therapeutic target.Drug discovery approaches to irritable bowel syndrome.Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.Ultra low-dose naloxone and tramadol/acetaminophen in elderly patients undergoing joint replacement surgery: a pilot study.Biphasic effects of naloxone in the rats receiving morphine overdose a place preference study.Low doses of alpha 2-adrenoceptor antagonists augment spinal morphine analgesia and inhibit development of acute and chronic tolerance.Insider access: pepducin symposium explores a new approach to GPCR modulation.A randomized clinical trial of the effects of ultra-low-dose naloxone infusion on postoperative opioid requirements and recovery.Possible delayed respiratory depression following intrathecal injection of morphine and bupivacaine in an alpaca.
P2860
Q24631740-F18D91FE-F736-48AC-8FCB-F58E0B97B7C1Q28488120-A583058C-B981-4A7D-9625-1FCD1DA916B2Q33372935-5C887CCD-504D-42BE-93B8-203B6C323396Q34051430-B7A56AB3-CF8B-4BAE-9DBC-69BBA2539638Q34144947-E2936950-5FFE-4E52-8CFC-9AEF59EFE9DCQ34354902-0524997D-CBDC-4EF8-B4A6-DF680BDC312FQ34524896-DF64E71D-D828-4C57-B1E7-E4B021DF61D1Q34660378-DD485482-05CB-4AC9-AB8A-002ACEA376DFQ34939624-CB29A782-6279-4E18-88B5-892CA3255530Q34939888-DA108A93-EBEE-4978-8D2C-E2A8BDCB4001Q34939914-CF3FBD07-BEF7-4B8B-8128-BD09F90A34A7Q35008902-0142794C-C85A-4CFE-BC0B-A4BD63262CDAQ35327954-B6BC6488-3E6D-44AB-9169-6ADD3B9530C4Q35884913-AA9A033E-C496-4CDB-9AF5-25A503D03288Q37114670-8F4356EB-F231-4F1D-B7B9-3D392C3966ACQ37680038-C67999A3-44A0-4358-B49A-213BC7667EA8Q37960735-1B46D3C0-EF55-4CD0-8532-7E39937CEB99Q37999097-123052F9-F82D-4A99-9A73-307FBD52D6F3Q38138785-71B4BC0D-5230-46E1-8420-F273E886D53FQ38210218-85C291EC-A81E-4C45-8B84-A6721713443AQ38266283-30C723A0-67A4-4AAA-9589-FB54BA2B0535Q38550878-E639FE53-57D2-463A-918E-2515DC979D92Q38659429-A59CD9CB-540B-49E9-BF8F-BC417B2655DCQ38675489-69F1AA2A-90D0-4331-84A9-29AEF82E6CB7Q38856699-9E84EB19-A9FC-4521-A239-507D964EDC62Q39970429-DBABA33E-08FF-4508-81C7-8461E2220668Q42927846-FDAF4786-C7DC-4687-9D23-EB787E0E9910Q43223809-35A3904D-D363-4499-9D4C-BC7BADCD0305Q43238652-6A902368-F0DF-499C-B453-010116C1278AQ44329973-66798EA9-8AB2-4C00-8C2D-E37C4DEA7050Q47840368-F9723CFF-248E-45A3-9F9D-CFD4927CA42C
P2860
Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Augmentation of spinal morphin ...... a-opioid receptor antagonists.
@ast
Augmentation of spinal morphin ...... a-opioid receptor antagonists.
@en
type
label
Augmentation of spinal morphin ...... a-opioid receptor antagonists.
@ast
Augmentation of spinal morphin ...... a-opioid receptor antagonists.
@en
prefLabel
Augmentation of spinal morphin ...... a-opioid receptor antagonists.
@ast
Augmentation of spinal morphin ...... a-opioid receptor antagonists.
@en
P2093
P2860
P356
P1476
Augmentation of spinal morphin ...... a-opioid receptor antagonists.
@en
P2093
P2860
P304
P356
10.1038/SJ.BJP.0707277
P407
P577
2007-05-14T00:00:00Z